These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31165603)

  • 1. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP; Mitkute D; Porter G; Vayalambrone D
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-Year Functional and Morphological Prognosis After Intravitreal Injection Treatments According to Different Morphological Patterns of Diabetic Macular Edema in Real-Life: MARMASIA Study Group Report No.13.
    Limon DU; Kaplan FB; Saygın I; Önder Tokuç E; Kutlutürk Karagöz I; Kanar HS; Sevik MO; Yayla U; Çelik E; Sönmez A; Aykut A; Kumral Türkseven E; Erçalık NY; Oncu Aydın Ö; Bozkurt E; Aydoğan T; Emengen EB; Özkaya A; Açıkalın Öncel B; Yenerel NM; Şahin Ö; Karabaş L
    Semin Ophthalmol; 2024 Aug; 39(6):460-467. PubMed ID: 39087722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
    Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
    BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
    Tsai MJ; Hsieh YT; Peng YJ
    Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ranibizumab, aflibercept, and dexamethasone implant monotherapy in treatment-naive eyes with diabetic macular edema: A 12-month real-life experience.
    Parca O; Cetin EN
    Indian J Ophthalmol; 2024 May; 72(Suppl 3):S453-S458. PubMed ID: 38648453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Adding Dexamethasone to Continued Ranibizumab Treatment in Patients With Persistent Diabetic Macular Edema: A DRCR Network Phase 2 Randomized Clinical Trial.
    Maturi RK; Glassman AR; Liu D; Beck RW; Bhavsar AR; Bressler NM; Jampol LM; Melia M; Punjabi OS; Salehi-Had H; Sun JK;
    JAMA Ophthalmol; 2018 Jan; 136(1):29-38. PubMed ID: 29127949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
    Sardana A; Singh K; Singh A; Singh VK
    Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranibizumab 0.5 mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study.
    Prünte C; Fajnkuchen F; Mahmood S; Ricci F; Hatz K; Studnička J; Bezlyak V; Parikh S; Stubbings WJ; Wenzel A; Figueira J;
    Br J Ophthalmol; 2016 Jun; 100(6):787-95. PubMed ID: 26453639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the effect of vitreomacular interface disorders on anti-VEGF treatment in patients with diabetic macular edema in real life: MARMASIA study group report No. 10.
    Bozkurt E; Kaplan FB; Önder Tokuç E; Aykut A; Özsoy Saygın I; Kanar HS; Kutlutürk I; Sevik MO; Yayla U; Çelik E; Demirciler Sönmez A; Aydogan Gezginaslan T; Limon U; Türkseven Kumral E; Erçalık NY; Aydın Öncü Ö; Başaran Emengen E; Özkaya A; Açıkalın Öncel B; Yenerel NM; Şahin Ö; Karabaş VL
    Int Ophthalmol; 2024 Sep; 44(1):391. PubMed ID: 39317810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema.
    Eriş E; Perente I; Vural E; Vural A; Seymen Z; Celebi ARC; Erdogan G; Ozkaya A; Artunay O
    Int Ophthalmol; 2019 Jul; 39(7):1575-1580. PubMed ID: 29943100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bevacizumab versus triamcinolone for persistent diabetic macular edema: a randomized clinical trial.
    Rodrigues MW; Cardillo JA; Messias A; Siqueira RC; Scott IU; Jorge R
    Graefes Arch Clin Exp Ophthalmol; 2020 Mar; 258(3):479-490. PubMed ID: 31873786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment.
    Karst SG; Lammer J; Mitsch C; Schober M; Mehta J; Scholda C; Kundi M; Kriechbaum K; Schmidt-Erfurth U
    Graefes Arch Clin Exp Ophthalmol; 2018 Jan; 256(1):49-58. PubMed ID: 29080915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
    Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
    JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF versus dexamethasone implant (Ozurdex) for the management of Centre involved Diabetic Macular Edema (CiDME): a randomized study.
    Sharma A; Bellala K; Dongre P; Reddy P
    Int Ophthalmol; 2020 Jan; 40(1):67-72. PubMed ID: 31377905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
    Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
    Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
    Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
    Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early response to ranibizumab predictive of functional outcome after dexamethasone for unresponsive diabetic macular oedema.
    Cicinelli MV; Cavalleri M; Querques L; Rabiolo A; Bandello F; Querques G
    Br J Ophthalmol; 2017 Dec; 101(12):1689-1693. PubMed ID: 28432109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.